Application of liraglutide in preparation of medicine for treating systemic lupus erythematosus
The inhibition of NADPH oxidase in neutrophils by liraglutide and reducing ROS and NETosis has solved the problems of severe side effects and poor blood sugar control in existing SLE treatment drugs, providing a safe and effective treatment of systemic lupus erythematosus New strategy.
Patent Information
- Application Number
- CN202411236852.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-04
- Publication Date
- 2024-12-06
AI Technical Summary
Existing SLE treatment drugs have serious side effects, especially hormone drugs do not control blood sugar and lack effective treatment methods for systemic lupus erythematosus.
Liraglutide and its derivatives were used to prepare anti-systemic lupus erythematosus drugs to inhibit the formation of NADPH oxidase in neutrophils, reduce ROS production and NETosis, thereby alleviating the condition of lupus mouse models.
Liraglutide significantly reduced the urine protein level in the lupus mouse model, reduced autoantibodies and immune complex deposition, improved renal pathological damage, and had high safety and lowering glycemic effects, suitable for patients with diabetes.
Smart Images

Figure CN119074899A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine, and in particular to the use of liraglutide and its derivatives in the preparation of drugs for treating systemic lupus erythematosus. Background Art
[0002] Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease that causes severe damage to multiple organs throughout the body. Its typical characteristics are the loss of autoimmune tolerance and the production of multiple autoantibodies, which form autoantigen-antibody immune complexes in the body, leading to the activation of the complement system. The main pathological changes are vascular lesions and inflammatory reactions. As a disease involving multiple systems, SLE often causes damage to multiple organs and tissues such as joints, kidneys, skin, lungs, central nervous system, and blood system. The clinical manifestations are complex and diverse. The more common target organ damage includes lupus nephritis (Lupus nephritis, LN), interstitial pneumonia, neuropsychiatric lupus, pleurisy, anemia and other blood system damage and pericarditis. About 60% of SLE patients will develop LN, which is also closely related to the prognosis and survival of SLE. Immune complexes are deposited on the renal tissue of LN patients, resulting in severe inflammatory damage to the renal parenchyma, which has a more serious impact on the prognosis of SLE patients and has become a major cause of death in SLE. So far, the etiology and pathogenesis of SLE are still not completely clear. Currently, researchers mainly believe that the onset of SLE is closely related to genetic factors, disordered hormone levels, abnormal immune regulation, viral and bacterial infections, and environmental factors. Since SLE patients have diverse clinical manifestations and the onset is affected by multiple conditions such as environment, race, and infection, there is still no specific drug for the treatment of SLE in clinical practice.
[0003] At present, the key factor in the development of systemic lupus erythematosus is believed to be the active death of neutrophils (PMN) (NETosis process). When the body is infected, neutrophils die, decondense their intracellular DNA, and release a special mesh structure to the outside of the cell. This special mesh structure with a large number of intracellular proteins attached is named neutrophile extracellular traps (NETs).
[0004] Previous studies have shown that reactive oxygen species (ROS) produced by neutrophils play a crucial role in the occurrence of most NETosis. ROS has high chemical reactivity and is a general term for a class of oxygen-containing molecules. Its characteristics are that some molecules with unpaired electrons are extremely unstable and reactive. ROS are mainly byproducts of oxygen reduction reactions and products of some enzymes related to respiratory burst. It is currently believed that the main sources of ROS in cells include mitochondria and NADPH oxidase. When the body is under oxidative stress, a large amount of ROS will be produced. When ROS is excessively produced in the body and is not cleared in time, it will damage the body's tissue cells and promote the development of SLE.
[0005] At present, the main clinical treatments for SLE are hormones and immunosuppressive drugs such as cyclosporine, hydroxychloroquine, cyclophosphamide, and methotrexate. Although they have certain therapeutic effects, they have serious side effects and can suppress the immune system and increase the possibility of infection. In addition, hormone drugs inevitably cause fluctuations in the patient's blood sugar, and there is a risk of aggravating the patient's original diabetes or causing potential diabetes. They may increase the demand for insulin or oral hypoglycemic drugs in diabetic patients, thereby increasing the chances of poor blood sugar control in patients with systemic lupus erythematosus and diabetes when using hormone drugs. Therefore, it is necessary to find new treatments for SLE. Summary of the invention
[0006] The purpose of the present invention is to overcome at least one deficiency of the prior art and provide the use of liraglutide and its derivatives in the preparation of drugs for treating systemic lupus erythematosus.
[0007] The technical solution adopted by the present invention is: In a first aspect, the present invention provides use of liraglutide or a derivative thereof in the preparation of an anti-systemic lupus erythematosus drug.
[0008] In a second aspect, the present invention provides the use of liraglutide or its derivatives in the preparation of a drug for inhibiting the formation of NADPH oxidase in neutrophils.
[0009] In some examples, the active ingredient in the drug is liraglutide and its derivatives, and also includes pharmaceutically acceptable excipients.
[0010] In some examples, the pharmaceutically acceptable excipients include at least one of a solvent, a filler, a lubricant, a disintegrant, a buffer, a solubilizing agent, an antioxidant, a bacteriostat, an emulsifier, a binder or a suspending agent.
[0011] In some examples, the drug is in the form of an intravenous injection, a suppository, a gel, a foam, an enteric solvent, a decoction, a mixture, a syrup, a granule, a pill, a capsule, a gel or a nanoformulation.
[0012] In some examples, the liraglutide derivative is selected from a pharmaceutically acceptable salt thereof.
[0013] The beneficial effects of the present invention are: In the present invention, liraglutide inhibits the expression of neutrophil NADPH oxidase, ROS production and NETosis, and finally alleviates the condition of the lupus mouse model to a certain extent, providing a new idea for the prevention and treatment of SLE in the clinic. As a drug commonly used in the clinic to treat type 2 diabetes, liraglutide has fewer side effects, higher safety, and glucose-lowering effect that is glucose concentration-dependent. It can have a glucose-lowering effect when blood sugar rises, and will not cause blood sugar to fall when blood sugar is normal. It may have a dual effect of improving lupus condition and assisting in regulating blood sugar for patients with systemic lupus erythematosus and diabetes, and is a potential treatment strategy with higher safety. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] Figure 1 Urine protein was measured in the Ctrl group, PIL group and PIL+Lira treatment group 8 weeks after grouping.
[0015] Figure 2 ELISA determination of serum anti-dsDNA antibody (left) and anti-Sm antibody (right) levels in the Ctrl group, PIL group, and PIL+Lira group.
[0016] Figure 3 HE staining of renal tissues in the Ctrl group, PIL group and PIL+Lira group.
[0017] Figure 4 Immunofluorescence staining of IgG (upper) and C3 (lower) in renal tissues of the Ctrl group, PIL group, and PIL+Lira group.
[0018] Figure 5 Immunofluorescence staining of MPO and citH3 in renal tissues of the Ctrl group, PIL group and PIL+Lira group.
[0019] Figure 6 Immunofluorescence staining of MPO and citH3 in bone marrow neutrophils of the Ctrl group, PIL group and PIL+Lira group.
[0020] Figure 7 Sytox Green fluorescence staining of bone marrow neutrophils in the Ctrl group, PIL group and PIL+Lira group.
[0021] Figure 8 The ROS production levels of bone marrow neutrophils in the Ctrl group, PIL group and PIL+Lira group. DETAILED DESCRIPTION
[0022] The following disclosure provides many different implementations or examples for implementing different solutions of the present invention. The Chinese-English abbreviations involved in the present invention are as follows. Abbreviations English full name Chinese full name SLE Systemic lupus erythematosus Systemic lupus erythematosus LN Lupus nephritis Lupus nephritis PMN Polymorphonuclear neutrophil Neutrophils NETs Neutrophil extracellular traps Neutrophil extracellular trap ROS Reactive Oxygen Species Active oxygen Lira Liraglutide Liraglutide
[0023] The experimental data of the present invention were all statistically analyzed using GraphPad Prism 8.0 software. The mean values of two groups of measurement data were compared using the t test, and the Levene variance homogeneity test method was used to verify the homogeneity of variance before the test. In the case of homogeneity of variance, the two independent sample t test (Independent-sample t test) method was used; if the variance was unequal, the Satterthwaite approximate t test was performed; the mean values of multiple groups of measurement data were compared using one-way analysis of variance (One-Way ANOVA), and P < 0.05 indicated that the mean difference was statistically significant. Example
[0024] 1) Construction of lupus mouse model The construction of the model mainly refers to the common modeling method from previous literature, that is, using pristane to inject BALB / c mice to construct lupus mice of PIL model. The main operation process is to perform a single intraperitoneal injection of 500ul pristane on female BALB / c mice aged 6-8 weeks. Be careful not to let pristane leak from the puncture point during the injection of the drug. The collection of mouse urine and the determination of urine protein began in the 6th week after the injection, and the urine protein was determined every two weeks for the next four weeks. The judgment method for the successful construction of the lupus mouse model is: in the 10th week after the injection, the urine protein measurement results of the mouse in the three urine protein tests were higher than 1 point for two consecutive times, which means that the lupus mouse model was successfully constructed.
[0025] 2) Grouping and dosing of mice After the mouse model was successfully established, the lupus mice were grouped based on the urine protein level, mainly divided into the following three groups: lupus mouse model group (PIL), Lira treatment group (PIL+Lira), and normal control group (Control).
[0026] The mice in the Lira treatment group were given subcutaneous injections of Lira at a dose of 200 mg / kg / day. Female BALB / c mice with similar weight and age to lupus mice were selected as the normal control group (Control) of this experiment. After 8 weeks of treatment, the mice were anesthetized with 1% sodium pentobarbital. After successful anesthesia, the eyeballs of the mice were removed and blood was collected, and the femur, tibia and kidney tissues of the mice were collected.
[0027] 3) Separation and extraction of peripheral venous blood serum from mice After obtaining blood from the mouse using the eyeball blood sampling method, the blood was collected into a marked EP tube, and then placed in a centrifuge adjusted to 4°C and centrifuged at 500g for 10 minutes. After centrifugation, the supernatant in the EP tube was carefully aspirated and stored in a newly marked EP tube, and stored in a -80° refrigerator for use.
[0028] 4) Mouse urine protein determination The urine protein of mice was tested using urine protein test strips, and urine protein was tested once every 2 weeks at the same time period.
[0029] 5) Detection of NETs in mouse bone marrow-derived neutrophils Neutrophils in the mouse bone marrow are separated and extracted using a mouse bone marrow neutrophil separation solution kit, comprising the following steps: S1 After the mice were anesthetized and killed, the tibia and femur on both sides of the mice were peeled off, and the two ends of the femur and tibia were carefully cut with scissors to fully expose the bone marrow cavity; S2 First use a syringe to suck out the homogenate flushing solution, and then flush the bone marrow in the mouse bone marrow cavity with an appropriate amount of flushing solution, flushing as much bone marrow as possible into the culture dish; S3: Repeatedly blow and beat the bone marrow in the culture dish until the bone marrow becomes a single cell suspension. Filter the single cell suspension with a 70um cell sieve and collect the filtrate into the prepared 15ml centrifuge tube; S4 Take the centrifuge tube out of the clean bench and place it in the centrifuge. Centrifuge at 450g for 10 minutes. After centrifugation, discard the supernatant in the tube. Use a pipette to draw 1ml of red blood cell sedimentation solution into the tube to resuspend the cells. S5 Use a pipette to suck 3 ml of separation solution into a newly prepared sterile siliconized centrifuge tube, then carefully and slowly add 1.5 ml of 80% separation solution into it. Pay attention to control the speed of adding samples and try to keep the gradient interface clear. S6: Pipette the resuspended cell suspension, hold the pipette against the wall of the siliconized centrifuge tube with separation solution, and carefully and slowly add the cell suspension along the tube wall. Be gentle and do not add the cell suspension below the liquid surface of the separation solution. Try to make the boundary between the two clear. After adding the cell suspension, carefully place the centrifuge tube in the centrifuge and centrifuge at 700g for 30 minutes. Be careful during the movement and try to keep the centrifuge tube stable to avoid shaking and mixing the liquid in the tube. S7 After the centrifugation is completed, the siliconized centrifuge tube is taken out. Two layers of white ring-shaped cell bands can be seen with the naked eye in the diluent layer. The lower cell band is the neutrophil band. Use a pipette to carefully suck out the lower layer of cells and place them in a new centrifuge tube. Then add the washing solution to the centrifuge tube. The volume of the washing solution added is about 3-5 times the volume of the cell suspension. Mix the two and centrifuge them in a centrifuge at a speed of 400g for 10 minutes. S8 After the centrifugation is completed, the supernatant in the centrifuge tube is discarded, and 200ul of red blood cell lysis solution is added to the centrifuge tube. The red blood cell lysis solution and the cell pellet are fully mixed, and the red blood cells are lysed at 4°C in the dark for 2 minutes, and then centrifuged at 300g for 10 minutes at room temperature; S9 After centrifugation, discard the supernatant outside the precipitate, resuspend the cell precipitate with an appropriate amount of RPMI-1640 solution, and centrifuge again at 300g for 10 minutes in a centrifuge; After S10 centrifugation, carefully aspirate and discard the supernatant, add 1 ml of RPMI-1640 to completely resuspend the cells, and then aspirate 10 ul of the cell suspension for cell counting. After counting, place the remaining cells in a cell culture incubator at 37°C and 5% CO2 for use.
[0030] S11 Immunofluorescence qualitative analysis and Sytox Green quantitative analysis were used to detect NETs in mouse bone marrow-derived neutrophils.
[0031] 6) Detection of ROS in mouse bone marrow-derived neutrophils After separating and extracting neutrophils from the mouse bone marrow using the mouse bone marrow neutrophil separation kit in the same manner as step 5), the specific method for ROS detection is as follows: After the neutrophils from the S1 mouse bone marrow are counted, they are placed in a new 1.5 ml EP tube; S2: Pipette 10uM DCFH-DA, add it into the EP tube containing bone marrow neutrophils and mix well. Then put the EP tube into a 37℃, 5% CO2 incubator for 20 minutes in the dark. Mix the liquid in the tube every 3-5 minutes. S3. Take the EP tube out of the incubator and put it into the centrifuge. Adjust the speed to 1000 rpm for centrifugation for 5 minutes. After the centrifugation, resuspend the neutrophils with RPMI-1640. Repeat the above operation three times to wash away the DCFH-DA that has not successfully entered the neutrophils. Keep it away from light throughout the whole process. S4 At this time, the neutrophils have been loaded with DCFH-DA probes. The cell suspension is added to a 96-well plate at a volume of 3 x 10^5 cells per well. The 96-well plate is then placed in a 37°C, 5% CO2 incubator for incubation in the dark for about 30 minutes. S5 Carefully take the 96-well plate out of the incubator, avoid light, and then place it in an ELISA reader for detection. The excitation wavelength is 485nm and the emission wavelength is 520nm.
[0032] 7) ELISA to detect the content of anti-dsDNA antibodies and anti-Sm antibodies in mouse serum The serum samples of the mice extracted in step 3) were tested using an ELISA kit containing anti-dsDNA antibodies.
[0033] 8) Evaluation of renal pathological damage in mice After the mouse was anesthetized successfully with sodium pentobarbital at a dose of 50 mg / kg and blood was collected from the eyeball, the mouse skin and subcutaneous fascia were cut along the midline of the mouse's abdomen, and the mouse kidney was carefully removed to prepare histopathological sections of the mouse kidney for use.
[0034] Then, hematoxylin-eosin staining (HE staining) was used to evaluate glomerular pathological damage using a semiquantitative scoring method. Twenty glomeruli were evaluated for each mouse, and the average of the total score was calculated as the final glomerular pathological score of the mouse.
[0035] Finally, by adding different primary antibodies, immunofluorescence staining was used to evaluate the deposition of immune complex IgG and C3 on the kidneys of mice and the deposition of NET on the kidneys of mice.
[0036] 9) Experimental results Effects of liraglutide on urinary protein in mouse models Figure 1 As shown. The PIL model mice were divided into groups at week 10. After 8 weeks of grouping and 8 weeks of Lira drug intervention, the increase in urine protein in the Lira treatment group was lower than that in the PIL group, and there was a statistically significant difference between the two groups (P=0.0109).
[0037] Effects of liraglutide on autoantibodies in mouse models Figure 2Compared with normal BALB / c mice (Control group), the content of anti-ds-DNA antibodies in the serum of the PIL group was significantly increased, and there was a significant statistical difference between the two (P<0.0001); while the serum anti-ds-DNA value of the Lira treatment group was significantly lower than that of the vehicle group, and there was a statistical difference (P=0.0494); The results of serum anti-Sm antibody detection were basically consistent with those of serum anti-ds-DNA detection. The serum anti-Sm antibody level in the PIL group was significantly higher than that in the Control group, and there was a significant statistical difference between the two groups (P=0.0004); compared with the PIL group, the serum anti-Sm antibody value in the Lira treatment group was significantly decreased, with a statistical difference (P=0.0465).
[0038] Effects of liraglutide on renal pathological changes in lupus mouse model Figure 3 As shown. Microscopic observation of renal tissue sections of mice in the Control group showed that the glomeruli were normal in size, with good morphological contours, and the gap between them and the adjacent renal capsule was clearly visible. There was no inflammatory cell infiltration in the renal interstitium, no hyperplasia in the mesangial area, and no renal vascular damage was observed in the renal tissue under the microscope. After HE staining of renal tissue sections of mice in the PIL group, microscopic observation showed that the glomerular morphology was unclear, the glomerular mesangial cells proliferated, the basement membrane was thickened, the collagen fiber deposition in the glomerulus and renal interstitium was heavy, a large number of inflammatory cells infiltrated in the interstitium, some glomeruli were focally sclerotic, and even severe fibrosis occurred. There was obvious renal vascular damage, increased cells in the capillaries, hyperplasia of endothelial cells, and thickening and obvious damage to the vascular wall. Compared with the PIL group, the glomerular morphology and contours of the Lira treatment group were more regular under the microscope, the gap between them and the adjacent renal capsule was clearer, and the inflammatory cell infiltration in the renal interstitium was significantly reduced, and the thickening and damage of the vascular wall was also significantly reduced. This indicates that the renal pathology of lupus mice was improved after Lira treatment.
[0039] Effects of liraglutide on glomerular immune complex IgG and C3 deposition in mouse models Figure 4 In the control group, there was basically no immune complex IgG and C3 deposition in the glomeruli under the fluorescence microscope, while in the PIL group, a large amount of IgG and C3 deposition was observed in the glomeruli. IgG and C3 were deposited in granular and lumpy forms along the capillary walls, mesangial areas and basement membranes of the glomeruli, and IgG deposition was also observed in the walls of some renal arterioles. Compared with the PIL group, the IgG and C3 deposition in the glomeruli and renal arteries in the Lira treatment group was significantly reduced.
[0040] Effects of liraglutide on glomerular NETs deposition in mouse models Figure 5As shown. In the control group, no obvious NETs were deposited in the glomeruli under a fluorescent microscope, while in the PIL group, a large number of blue (DAPI) and red (MPO) co-localized, blue (DAPI) and green (citH3) co-localized NETs were observed in the glomeruli under a microscope after staining of the renal tissue sections; and compared with the PIL group, the NETs deposition in the glomeruli in the Lira treatment group was significantly reduced.
[0041] Effects of liraglutide on NETosis in bone marrow-derived neutrophils in a mouse model Figure 6 After the bone marrow-derived neutrophils of each group of mice were cultured in vitro for 4 hours, the results were observed under a fluorescence microscope. No obvious NETs were formed in the bone marrow-derived neutrophils of the Control group, while a large number of NETs co-localized with blue (DAPI) and red (MPO) and blue (DAPI) and green (citH3) could be observed under the microscope after staining of the neutrophils in the PIL group. Compared with the PIL group, the production of NETs by neutrophils in the Lira treatment group was significantly reduced.
[0042] Effects of liraglutide on NETosis in bone marrow-derived neutrophils in a mouse model Figure 7 The production of NETs in bone marrow-derived neutrophils of the above-mentioned groups of mice was quantitatively compared by fluorescence intensity of a multifunctional microplate reader. Compared with the Control group, there was no statistically significant difference in the fluorescence intensity value of the Lira treatment group, while the fluorescence intensity reading of the PIL group was significantly higher than that of the Control group; compared with the PIL group, the fluorescence intensity reading of the Lira treatment group was significantly decreased.
[0043] Effects of liraglutide on ROS in bone marrow-derived neutrophils in mouse models Figure 8 The difference in ROS production of bone marrow-derived neutrophils in each group of mice was detected by an ELISA instrument. The results showed that the fluorescence intensity of bone marrow-derived neutrophils in the PIL group was significantly higher than that in the Control group, and there was a significant statistical difference between the two groups; while in the Lira treatment group, the fluorescence intensity reading was lower than that in the PIL group, and there was a statistical difference between the two groups.
[0044] 10) Experimental summary In this embodiment, after 8 weeks of treatment with Lira, the urine protein, anti-Sm antibodies, and anti-dsDNA antibodies of the lupus mouse model decreased significantly, and the pathological damage and immune complex deposition in the kidneys of the lupus mice were improved. In addition, Lira inhibited the spontaneous production of ROS and NETosis by bone marrow-derived neutrophils in the lupus mouse model, and also reduced the deposition of NETs on the kidneys of lupus mice. In summary, Lira is likely to reduce ROS, inhibit NETosis, and thus play a therapeutic role in lupus mice.
[0045] The above is a further detailed description of the present invention, which should not be regarded as a limitation on the specific implementation of the present invention. For ordinary technicians in the technical field to which the present invention belongs, simple deduction or replacement without departing from the concept of the present invention is within the protection scope of the present invention.
Claims
1. Use of liraglutide or its derivatives in the preparation of anti-systemic lupus erythematosus drugs.
2. Use of liraglutide or its derivatives in the preparation of drugs for inhibiting the formation of NADPH oxidase in neutrophils.
3. The use according to claim 1 or 2, characterized in that: The active ingredient of the medicine is liraglutide and its derivatives, and also includes pharmaceutically acceptable excipients.
4. The use according to claim 3, characterized in that: The pharmaceutically acceptable excipients include at least one of a solvent, a filler, a lubricant, a disintegrant, a buffer, a solubilizing agent, an antioxidant, an antibacterial agent, an emulsifier, a binder or a suspending agent.
5. The use according to claim 3, characterized in that: The drug is in the form of intravenous injection, suppository, gel, foam, enteric solvent, decoction, mixture, syrup, granule, pill, capsule, gel or nano preparation.
6. The use according to claim 3, characterized in that: The liraglutide derivative is selected from pharmaceutically acceptable salts thereof.
